

Criteria and Instructions for Referral of Patients with Oligometastatic Disease for SABR at Bristol Cancer Institute

Oligometastases (3 sites or less)		
Site	Currently available at Bristol	Comments
Lung	Yes	
Bone (non spine)	Yes	From end July 16
Spine	No	
Lymph nodes	Yes	From end July 16
Adrenal	Yes	From end July 16
Liver	Yes	From end July 16
Re-irradiation of pelvis	No	Available at selected centres

General criteria

- Metastatic Cancer with either a histologically or cytologically proven primary site (or a male patient with PSA>50 and clinical evidence of prostate cancer)
- 1 – 3 sites of metastatic disease
- Maximum size of any single metastasis of 6cm (5cm for lung or liver)
- Disease free interval between primary treatment and development of metastases >6 months
- Life expectancy > 6 months
- Performance status 0 – 2
- Exclude patients who have had previous radiotherapy within the planned treatment volume
- Prior discussion with disease site specific oncologist
- Prostate/Lung/Breast – once CORE trial open these patients will not be eligible for CtE

Site Specific criteria

Lung

- Histologically or radiologically confirmed lung metastases
- Not suitable for surgery due to co-morbidities, inadequate lung function or disease status
- Peripherally located lung metastases (>2cm from radius of main airways and proximal bronchial tree)

Lymph nodes

- Exclude patients requiring irradiation of whole nodal field

Adrenal

- Absent or limited and potentially treatable extra-adrenal disease
- Systemic therapy completed (or discontinued 4 weeks before SABR started)

Criteria and Instructions for Referral of Patients with Oligometastatic Disease for SABR at Bristol Cancer Institute

Liver

- 1 – 3 liver metastases on contrast enhanced CT and/or MRI
- Unresectable, patient unfit for surgery or presence of extra-hepatic disease makes surgery inappropriate
- Childs-Pugh Class A
- Adequate hepatic function:
 - >700cc normal liver (liver volume-gross tumour volume)
 - Bilirubin < 3 x upper limit of normal
 - NR < 1.3
 - ALT < 5 x upper limit of normal
 - Platelets > 80
- Exclude patients with active hepatitis or clinically significant liver failure, clinically apparent ascites or CNS metastases
- Patient suitability established at Hepatobiliary MDT prior to referral

Instructions for referral

Please send your referral letter from a secure nhs.net email account to the following group email account:

ubh-tr.SABRteam@nhs.net

Please also send the results of any relevant tests e.g. lung function, liver function to this address

Please make available any recent scans for the team in Bristol to view

If you are referring from another Hospital Trust please complete an Inter-provider Transfer Form and email to the above address

Any further queries should be directed via the email account or to:

Sarah Sheppard
SABR Co-ordinator
01173423970

Jancis Kinsman
SABR Lead Radiographer
01173424469

Dr Charles Comins
SABR Clinical Lead
01173423176